Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABI-M201

Other · developed by Assembly Biosciences

Phase 1 Most advanced trial (none active)
ASMB Developer
1 Registered trials

What is ABI-M201?

ABI-M201 is an investigational agent studied in chronic mild and chronic moderate ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Assembly Biosciences (ASMB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03923478 Phase 1 Ulcerative Colitis Chronic Mild Terminated ASMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis Chronic MildUlcerative Colitis Chronic Moderate

More from Assembly Biosciences

ABI-1179 Phase 1 ABI-4334 Phase 1 ABI-5366 Phase 1 ABI-6250 Phase 2 ABI-H2158 Phase 2 ABI-H3733 Phase 1 Peg-IFNα Phase 2 Vebicorvir Phase 2

Follow ASMB, the company behind ABI-M201

See ASMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASMB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.